Trial Profile
Safety and immunogenicity of V 212 in adults with solid tumour malignancy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Jun 2011
Price :
$35
*
At a glance
- Drugs V 212 (Primary)
- Indications Varicella zoster virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck & Co
- 23 Jun 2011 New trial record